The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal function in Parkinson’s disease (PD) and other neurodegenerative ...

The UK government’s £26 billion NHS investment has enabled 80,000 more people to receive cancer diagnoses or all-clear results within 28 days The government’s largest-ever investment in the NHS is ...

A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." Authored by Dr. Naina ...

In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer Prostate cancer is one of the most ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

Diagnostic imaging plays an important role in identifying cancerous areas, which may help guide treatment decisions. Trofolastat is combined with the radioactive tracer technetium-99m to form ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...